Form 4: Axsome Therapeutics Director Mark Coleman Sells 3,000 Shares

Director Mark Coleman of Axsome Therapeutics sold 3,000 shares of common stock at an average price of $107.491 on May 20, 2025.

Summary

• On May 20, 2025, Mark Coleman, a director of Axsome Therapeutics, sold 3,000 shares of common stock.
• The sale was executed at a weighted average price of $107.491 per share, with individual sale prices ranging from $107.34 to $107.65.
• Following the transaction, Coleman directly owns 54,137 shares and indirectly owns 403,856 shares through an entity where he holds voting and dispositive power.

Sentiment

Score: 5

Explanation: This is a neutral event. A director selling shares doesn't necessarily indicate a negative outlook, as it could be for personal financial reasons.

Industry Context

This is a routine disclosure of insider trading activity. It's common for directors and officers to buy and sell shares of their company's stock. The impact on the stock price is usually minimal unless the transaction is very large or part of a broader trend.

Stakeholder Impact

• The sale of shares by a director could have a minor psychological impact on shareholders, but the effect is likely to be minimal given the size of the transaction.

Key Dates

Keywords

Axsome Therapeutics, Director, Share Sale, Mark Coleman, Common Stock, Form 4